Patents by Inventor Vladimir Joukov

Vladimir Joukov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DYNAMIC ADJUSTABLE EXERCISE SYSTEM
    Publication number: 20220355163
    Abstract: An adjustable weight exercise system is provided. A permanent weight assembly and a plurality of interlocking weights are provided. A base comprises an interlocking weight carrier, wherein the interlocking weights are supported on the interlocking weight carrier and an interlocking weight selector, wherein the interlocking weight selector is adapted to cause interlocking weights to be set to be locked to the permanent weight assembly while the permanent weight assembly is not on the base, wherein placement of the permanent weight assembly on the base causes interlocking weights that are set to be locked to the permanent weight assembly to be locked to the permanent weight assembly, and wherein placement of the permanent weight assembly on the base does not cause interlocking weights that are not set to be locked to the permanent weight assembly to be locked to the permanent weight assembly.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 10, 2022
    Inventors: Kareem ALY, Brian P. LOVERA, Vladimir JOUKOV, Michael Chad MAKAY
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 8637262
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 28, 2014
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 8282931
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 9, 2012
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
    Publication number: 20110135649
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Application
    Filed: September 10, 2010
    Publication date: June 9, 2011
    Applicant: VEGENICS PTY LIMITED
    Inventors: KARI ALITALO, VLADIMIR JOUKOV
  • VEGF-C ?R?Rmutants and uses thereof
    Patent number: 7807412
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 5, 2010
    Assignee: Vegenies Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Methods of using antibodies to VEGF-C
    Patent number: 7794756
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: September 14, 2010
    Assignee: Vegenics Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 7727761
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: June 1, 2010
    Assignee: Vegenics Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein diagnostic
    Patent number: 7709270
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 4, 2010
    Assignee: Vegenics Ltd.
    Inventors: Kari Alitalo, Vladimir Joukov
  • VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) PROTEIN AND GENE, MUTANTS THEREOF, AND USES THEREOF
    Publication number: 20090104198
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: October 30, 2007
    Publication date: April 23, 2009
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
    Publication number: 20080241152
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 2, 2008
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
    Publication number: 20080241153
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 2, 2008
    Inventors: KARI ALITALO, Vladimir Joukov
  • Antibodies to VEGF-C
    Patent number: 7423125
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: September 9, 2008
    Assignee: Vegenics Limited
    Inventors: Kari Alitalo, Vladimir Joukov
  • Progenitor cell materials and methods
    Patent number: 7125714
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: October 24, 2006
    Assignees: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
    Patent number: 6818220
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: November 16, 2004
    Assignees: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Publication number: 20040147726
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 29, 2004
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Publication number: 20040147448
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 29, 2004
    Inventors: Kari Alitalo, Vladimir Joukov
  • Stimulation of lymphatic growth with an FLT4 ligand
    Patent number: 6730658
    Abstract: Provided are methods of stimulating the growth of lymphatic endothelia using an Flt4 ligand.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: May 4, 2004
    Assignees: Helsinki University Licensing, Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Receptor ligand VEGF-C
    Patent number: 6645933
    Abstract: Provided are polypeptide ligands for the receptor tyrosine kinase, Flt4. Also provided are cDNAs and vectors encoding the ligands, pharmaceutical compositions and diagnostic reagents comprising the ligands, and methods of making and using the ligands.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: November 11, 2003
    Assignees: Helsinki University Licensing Ltd. Oy, Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Progenitor cell materials and methods
    Publication number: 20030091567
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: July 23, 2002
    Publication date: May 15, 2003
    Inventors: Kari Alitalo, Vladimir Joukov
  • Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
    Patent number: 6403088
    Abstract: The invention provides antibodies that are reactive with VEGF-C, a polypeptide ligand for Flt4 receptor tyrosine kinase (VEGFR-3).
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: June 11, 2002
    Assignees: Helsinki University Licensing, Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov